{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:45:42Z","timestamp":1781541942164,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"DOI":"10.7759\/cureus.89911","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T16:59:50Z","timestamp":1755017990000},"source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological Interventions for Orthostatic Hypotension: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Anushka","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiman","family":"Saraya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehjabin  S","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithum","family":"Senaratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safiyyah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alousious","family":"Kasagga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iana A","family":"Malasevskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-011-0119-5","article-title":"Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome","volume":"21","author":"Freeman R","year":"2011","unstructured":"Freeman R, Wieling W, Axelrod FB, et al.. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011, 21:69-72. 10.1007\/s10286-011-0119-5","journal-title":"Clin Auton Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.05.079","article-title":"Orthostatic hypotension: JACC state-of-the-art review","volume":"72","author":"Freeman R","year":"2018","unstructured":"Freeman R, Abuzinadah AR, Gibbons C, Jones P, Miglis MG, Sinn DI. Orthostatic hypotension: JACC state-of-the-art review. J Am Coll Cardiol. 2018, 72:1294-309. 10.1016\/j.jacc.2018.05.079","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.06.1084","article-title":"Orthostatic hypotension: epidemiology, prognosis, and treatment","volume":"66","author":"Ricci F","year":"2015","unstructured":"Ricci F, De Caterina R, Fedorowski A. Orthostatic hypotension: epidemiology, prognosis, and treatment. J Am Coll Cardiol. 2015, 66:848-60. 10.1016\/j.jacc.2015.06.1084","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2011.08.008","article-title":"Orthostatic hypotension: a common, serious and underrecognized problem in hospitalized patients","volume":"6","author":"Feldstein C","year":"2012","unstructured":"Feldstein C, Weder AB. Orthostatic hypotension: a common, serious and underrecognized problem in hospitalized patients. J Am Soc Hypertens. 2012, 6:27-39. 10.1016\/j.jash.2011.08.008","journal-title":"J Am Soc Hypertens"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2020.102717","article-title":"Morbidity and mortality in orthostatic hypotension","volume":"229","author":"Farrell MC","year":"2020","unstructured":"Farrell MC, Shibao CA. Morbidity and mortality in orthostatic hypotension. Auton Neurosci. 2020, 229:102717. 10.1016\/j.autneu.2020.102717","journal-title":"Auton Neurosci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2015.08.020","article-title":"Orthostatic hypotension in diabetic patients-10-year follow-up study","volume":"30","author":"Gaspar L","year":"2016","unstructured":"Gaspar L, Kruzliak P, Komornikova A, et al.. Orthostatic hypotension in diabetic patients-10-year follow-up study. J Diabetes Complications. 2016, 30:67-71. 10.1016\/j.jdiacomp.2015.08.020","journal-title":"J Diabetes Complications"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2011.04.016","article-title":"Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis","volume":"17","author":"Velseboer DC","year":"2011","unstructured":"Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM. Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2011, 17:724-9. 10.1016\/j.parkreldis.2011.04.016","journal-title":"Parkinsonism Relat Disord"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2020.102713","article-title":"Differential diagnosis of orthostatic hypotension","volume":"228","author":"Lei LY","year":"2020","unstructured":"Lei LY, Chew DS, Raj SR. Differential diagnosis of orthostatic hypotension. Auton Neurosci. 2020, 228:102713. 10.1016\/j.autneu.2020.102713","journal-title":"Auton Neurosci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glad221","article-title":"Cardiovascular disorders and falls among older adults: a systematic review and meta-analysis","volume":"79","author":"Bourke R","year":"2024","unstructured":"Bourke R, Doody P, P\u00e9rez S, Moloney D, Lipsitz LA, Kenny RA. Cardiovascular disorders and falls among older adults: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci. 2024, 79:10.1093\/gerona\/glad221","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2014.00471","article-title":"Syncope: epidemiology, etiology, and prognosis","volume":"5","author":"da Silva RM","year":"2014","unstructured":"da Silva RM. Syncope: epidemiology, etiology, and prognosis. Front Physiol. 2014, 5:471. 10.3389\/fphys.2014.00471","journal-title":"Front Physiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-018-1129-x","article-title":"Characterization of the symptoms of neurogenic orthostatic hypotension and their impact from a survey of patients and caregivers","volume":"18","author":"Claassen DO","year":"2018","unstructured":"Claassen DO, Adler CH, Hewitt LA, Gibbons C. Characterization of the symptoms of neurogenic orthostatic hypotension and their impact from a survey of patients and caregivers. BMC Neurol. 2018, 18:125. 10.1186\/s12883-018-1129-x","journal-title":"BMC Neurol"},{"key":"ref12","article-title":"Orthostatic hypotension: a practical approach","volume":"105","author":"Kim MJ","year":"2022","unstructured":"Kim MJ, Farrell J. Orthostatic hypotension: a practical approach. Am Fam Physician. 2022, 105:39-49.","journal-title":"Am Fam Physician"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.11124\/JBISRIR-D-18-00005","article-title":"Effectiveness of non-pharmacological interventions to treat orthostatic hypotension in elderly people and people with a neurological condition: a systematic review","volume":"18","author":"Logan A","year":"2020","unstructured":"Logan A, Freeman J, Pooler J, et al.. Effectiveness of non-pharmacological interventions to treat orthostatic hypotension in elderly people and people with a neurological condition: a systematic review. JBI Evid Synth. 2020, 18:2556-617. 10.11124\/JBISRIR-D-18-00005","journal-title":"JBI Evid Synth"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00317-5","article-title":"Durability of the clinical benefit of droxidopa for neurogenic orthostatic hypotension during 12 weeks of open-label treatment","volume":"11","author":"Hauser RA","year":"2022","unstructured":"Hauser RA, Favit A, Hewitt LA, Lindsten A, Gorny S, Kymes S, Isaacson SH. Durability of the clinical benefit of droxidopa for neurogenic orthostatic hypotension during 12 weeks of open-label treatment. Neurol Ther. 2022, 11:459-69. 10.1007\/s40120-021-00317-5","journal-title":"Neurol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000615","article-title":"Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial","volume":"83","author":"Kaufmann H","year":"2014","unstructured":"Kaufmann H, Freeman R, Biaggioni I, et al.. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014, 83:328-35. 10.1212\/WNL.0000000000000615","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.04035","article-title":"Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa","volume":"65","author":"Biaggioni I","year":"2015","unstructured":"Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2015, 65:101-7. 10.1161\/HYPERTENSIONAHA.114.04035","journal-title":"Hypertension"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-160860","article-title":"Safety and durability of effect with long-term, open-label droxidopa treatment in patients with symptomatic neurogenic orthostatic hypotension (NOH303)","volume":"6","author":"Isaacson S","year":"2016","unstructured":"Isaacson S, Shill HA, Vernino S, Ziemann A, Rowse GJ. Safety and durability of effect with long-term, open-label droxidopa treatment in patients with symptomatic neurogenic orthostatic hypotension (NOH303). J Parkinsons Dis. 2016, 6:751-9. 10.3233\/JPD-160860","journal-title":"J Parkinsons Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-130259","article-title":"Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A)","volume":"4","author":"Hauser RA","year":"2014","unstructured":"Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). J Parkinsons Dis. 2014, 4:57-65. 10.3233\/JPD-130259","journal-title":"J Parkinsons Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26086","article-title":"Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B)","volume":"30","author":"Hauser RA","year":"2015","unstructured":"Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). Mov Disord. 2015, 30:646-54. 10.1002\/mds.26086","journal-title":"Mov Disord"},{"key":"ref20","article-title":"Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study","volume":"277","author":"Low PA","year":"1997","unstructured":"Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. JAMA. 1997, 277:1046-51.","journal-title":"JAMA"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1016\/0002-9343(93)90230-M","article-title":"Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine","volume":"95","author":"Jankovic J","year":"1993","unstructured":"Jankovic J, Gilden JL, Hiner BC, et al.. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993, 95:38-48.","journal-title":"Am J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.51.1.120","article-title":"A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension","volume":"51","author":"Wright RA","year":"1998","unstructured":"Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN, Low PA. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998, 51:120-4. 10.1212\/wnl.51.1.120","journal-title":"Neurology"},{"key":"ref23","unstructured":"ClinicalTrials.gov. Study to assess the benefit of midodrine in the treatment of patients with neurogenic orthostatic hypotension. (2021). Accessed. November 27, 2024: https:\/\/clinicaltrials.gov\/study\/NCT00555880."},{"key":"ref24","unstructured":"ClinicalTrials.gov. A study for patients with neurogenic orthostatic hypotension. (2021). Accessed. November 27, 2024: https:\/\/clinicaltrials.gov\/study\/NCT00046475."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004340","article-title":"Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension","volume":"89","author":"Byun JI","year":"2017","unstructured":"Byun JI, Moon J, Kim DY, et al.. Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension. Neurology. 2017, 89:1078-86. 10.1212\/WNL.0000000000004340","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-024-01051-2","article-title":"Atomoxetine on neurogenic orthostatic hypotension: a randomized, double-blind, placebo-controlled crossover trial","volume":"34","author":"Mwesigwa N","year":"2024","unstructured":"Mwesigwa N, Millar Vernetti P, Kirabo A, et al.. Atomoxetine on neurogenic orthostatic hypotension: a randomized, double-blind, placebo-controlled crossover trial. Clin Auton Res. 2024, 34:561-9. 10.1007\/s10286-024-01051-2","journal-title":"Clin Auton Res"},{"key":"ref27","unstructured":"ClinicalTrials.gov. Norepinephrine transporter blockade in autonomic failure (NETAF). (2023). https.\/\/clinicaltrials.gov\/study\/NCT02784535."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.11790","article-title":"Synergistic pressor effect of atomoxetine and pyridostigmine in patients with neurogenic orthostatic hypotension","volume":"73","author":"Okamoto LE","year":"2019","unstructured":"Okamoto LE, Shibao CA, Gamboa A, et al.. Synergistic pressor effect of atomoxetine and pyridostigmine in patients with neurogenic orthostatic hypotension. Hypertension. 2019, 73:235-41. 10.1161\/HYPERTENSIONAHA.118.11790","journal-title":"Hypertension"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.04225","article-title":"Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure","volume":"64","author":"Ramirez CE","year":"2014","unstructured":"Ramirez CE, Okamoto LE, Arnold AC, et al.. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2014, 64:1235-40. 10.1161\/HYPERTENSIONAHA.114.04225","journal-title":"Hypertension"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.50968","article-title":"Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension","volume":"7","author":"Byun JI","year":"2020","unstructured":"Byun JI, Kim DY, Moon J, et al.. Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension. Ann Clin Transl Neurol. 2020, 7:112-20. 10.1002\/acn3.50968","journal-title":"Ann Clin Transl Neurol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.4.noc50340","article-title":"Pyridostigmine treatment trial in neurogenic orthostatic hypotension","volume":"63","author":"Singer W","year":"2006","unstructured":"Singer W, Sandroni P, Opfer-Gehrking TL, et al.. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006, 63:513-8. 10.1001\/archneur.63.4.noc50340","journal-title":"Arch Neurol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.74.9.1294","article-title":"Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension","volume":"74","author":"Singer W","year":"2003","unstructured":"Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2003, 74:1294-8. 10.1136\/jnnp.74.9.1294","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13260","article-title":"Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial","volume":"24","author":"Schreglmann SR","year":"2017","unstructured":"Schreglmann SR, B\u00fcchele F, Sommerauer M, et al.. Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial. Eur J Neurol. 2017, 24:545-51. 10.1111\/ene.13260","journal-title":"Eur J Neurol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21428","article-title":"Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease","volume":"22","author":"Schoffer KL","year":"2007","unstructured":"Schoffer KL, Henderson RD, O'Maley K, O'Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord. 2007, 22:1543-9. 10.1002\/mds.21428","journal-title":"Mov Disord"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.2337\/diab.24.4.381","article-title":"9-Alpha-fluorohydrocortisone in the treatment of postural hypotension in diabetic autonomic neuropathy","volume":"24","author":"Campbell IW","year":"1975","unstructured":"Campbell IW, Ewing DJ, Clarke BF. 9-Alpha-fluorohydrocortisone in the treatment of postural hypotension in diabetic autonomic neuropathy. Diabetes. 1975, 24:381-4. 10.2337\/diab.24.4.381","journal-title":"Diabetes"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-005-0288-1","article-title":"Fludrocortisone in patients with familial dysautonomia. Assessing effect on clinical parameters and gene expression","volume":"15","author":"Axelrod FB","year":"2005","unstructured":"Axelrod FB, Goldberg JD, Rolnitzky L, et al.. Fludrocortisone in patients with familial dysautonomia. Assessing effect on clinical parameters and gene expression. Clin Auton Res. 2005, 15:284-91. 10.1007\/s10286-005-0288-1","journal-title":"Clin Auton Res"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.2.4534","article-title":"Treatment of orthostatic hypotension with midodrine and octreotide","volume":"83","author":"Hoeldtke RD","year":"1998","unstructured":"Hoeldtke RD, Horvath GG, Bryner KD, Hobbs GR. Treatment of orthostatic hypotension with midodrine and octreotide. J Clin Endocrinol Metab. 1998, 83:339-43. 10.1210\/jcem.83.2.4534","journal-title":"J Clin Endocrinol Metab"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199502000-00012","article-title":"Octreotide effects on orthostatic hypotension in patients with multiple system atrophy: a controlled study of acute administration","volume":"18","author":"Bordet R","year":"1995","unstructured":"Bordet R, Benhadjali J, Dest\u00e9e A, Belabbas A, Libersa C. Octreotide effects on orthostatic hypotension in patients with multiple system atrophy: a controlled study of acute administration. Clin Neuropharmacol. 1995, 18:83-9. 10.1097\/00002826-199502000-00012","journal-title":"Clin Neuropharmacol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt GH","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008, 336:924-6. 10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016, 5:210. 10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1097\/XEB.0000000000000055","article-title":"Summarizing systematic reviews. Methodological development, conduct and reporting of an umbrella review approach","volume":"13","author":"Aromataris E","year":"2015","unstructured":"Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P. Summarizing systematic reviews. Methodological development, conduct and reporting of an umbrella review approach. Int J Evid Based Healthc. 2015, 13:132-40. 10.1097\/XEB.0000000000000055","journal-title":"Int J Evid Based Healthc"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang A","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010, 25:603-5. 10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias visualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness LA","year":"2021","unstructured":"McGuinness LA, Higgins JP. Risk-of-bias visualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021, 12:55-61. 10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-011-0146-2","article-title":"The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale","volume":"22","author":"Kaufmann H","year":"2012","unstructured":"Kaufmann H, Malamut R, Norcliffe-Kaufmann L, Rosa K, Freeman R. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. 2012, 22:79-90. 10.1007\/s10286-011-0146-2","journal-title":"Clin Auton Res"},{"key":"ref47","article-title":"The Clinical Global Impressions Scale. Applying a research tool in clinical practice","volume":"4","author":"Busner J","year":"2007","unstructured":"Busner J, Targum SD. The Clinical Global Impressions Scale. Applying a research tool in clinical practice. Psychiatry (Edgmont). 2007, 4:28-37.","journal-title":"Psychiatry (Edgmont)"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12122","article-title":"A systematic review of the pharmacological management of orthostatic hypotension","volume":"67","author":"Ong AC","year":"2013","unstructured":"Ong AC, Myint PK, Shepstone L, Potter JF. A systematic review of the pharmacological management of orthostatic hypotension. Int J Clin Pract. 2013, 67:633-46. 10.1111\/ijcp.12122","journal-title":"Int J Clin Pract"},{"key":"ref49","article-title":"Efficacy of pharmacological management of orthostatic hypotension- a systematic review and meta-analysis","author":"Kulkarni S","year":"2022","unstructured":"Kulkarni S, Jenkins D, Pavey H, Phillips V, Mir F. Efficacy of pharmacological management of orthostatic hypotension- a systematic review and meta-analysis. Authorea. 2022,","journal-title":"Authorea"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2020.102721","article-title":"Pharmacologic treatment of orthostatic hypotension","volume":"229","author":"Park JW","year":"2020","unstructured":"Park JW, Okamoto LE, Shibao CA, Biaggioni I. Pharmacologic treatment of orthostatic hypotension. Auton Neurosci. 2020, 229:102721. 10.1016\/j.autneu.2020.102721","journal-title":"Auton Neurosci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/398619-pharmacological-interventions-for-orthostatic-hypotension-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T16:59:52Z","timestamp":1755017992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/398619-pharmacological-interventions-for-orthostatic-hypotension-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":50,"URL":"https:\/\/doi.org\/10.7759\/cureus.89911","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}